PMA device
Crystalens Accommodating Posterior Chamber Intraocular Lens (Aiol)
Bausch & Lomb, Inc. · Lens, Intraocular, Accommodative (NAA, Class III) · First FDA decision Jun 19, 2008, newest Jun 19, 2008Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Crystalens Accommodating Posterior"
MAUDE reports
0
Brand "Crystalens Accommodating Posterior", since 2015
PubMed studies
0
Mentioning "Crystalens Accommodating Posterior"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Crystalens Accommodating Posterior Chamber Intraocular Lens (Aiol)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- CRYSTALENS ACCOMMODATING POSTERIOR CHAMBER INTRAOCULAR LENS (AIOL), MODELS AT-45-HD100, HD500, AND HD520PMA supplement
P030002-S014 · Decided Jun 19, 2008 · 185 days after receipt · Normal 180 Day Track
Device type: Lens, intraocular, accommodative (NAA) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Crystalens Accommodating Posterior", any status and sponsor, newest update first.
- Toric Intraocular Lens Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedNot on our public-company list
NCT01140477 · 229 participants · Start Jun 2010 · Primary completion Dec 2011
Device: Toric Accommodating Lens; Accommodating Lens · For: Cataract; Astigmatism
Sites: Bridgewater, New Jersey
Bausch & Lomb IncorporatedNot on our public-company list
NCT01225952 · 93 participants · Start Jul 2010 · Primary completion Jun 2011
Device: Crystalens AO; ReSTOR 3.0 and 1 more · For: Cataract
Sites: Makati City, Philippines
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Crystalens Accommodating Posterior", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NAA
589 reports: 4 malfunction, 583 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0445-2012 · Started Nov 14, 2011 · Posted by FDA Jan 11, 2012
Reason given: Bausch + Lomb voluntary initiated the recall due to a physician complaint of haze on the Crystalens AO which was visualized using an angled beam from a slit lamp during the post-operative examination.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Lens, Intraocular, Accommodative (NAA)
Published research
The most relevant PubMed records for "Crystalens Accommodating Posterior"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NAA.
- Crystalens Model AT-45 Accommodating Intraocular LensBausch & Lomb, Inc. · PMA 2011
- Trulign® Toric Posterior Chamber Intraocular Lens (IOL)Bausch & Lomb, Inc. · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.